Vanderbilt-Ingram Cancer Center

Symposium offers new ways to overcome health disparities

Ideas for addressing the disproportionate impact of cancer, diabetes, and gastrointestinal diseases on disadvantaged populations were shared recently during a diversity symposium at Vanderbilt University Medical Center.

photo of William Dupont

Study discovers that tumor mutation burden predicts survival outcome

The expected course of a patient’s cancer prognosis has traditionally been judged by its type, stage and microscopic aggressiveness, but patients with the same presentation can still have widely divergent outcomes. Researchers from Vanderbilt-Ingram Cancer Center have discovered that differences in tumor mutation burden are a major reason for this divergence.

Liquid biopsy test may detect early-stage and low DNA-shedding cancers

Vanderbilt research shows that a liquid biopsy-based multicancer early detection (MCED) test could detect 12 types of cancers, including low DNA-shedding cancers and early-stage cancers.

Spring event honors donors’ support and generosity

Members of Vanderbilt University Medical Center’s Canby Robinson Society recently joined CEO and President Jeff Balser, MD, PhD, and his wife, Melinda, at Cheekwood Botanic Hall for the Spring Donor Celebration, an annual event honoring donors for their loyal support.

Lovly elected to American Association for Cancer Research board

Christine Lovly, MD, PhD, has been elected to the American Association for Cancer Research board of directors.

Genomic analysis of SCLC tumors reveals subtypes, offers cues toward personalized treatments

The largest genomic analysis ever conducted of small cell lung cancer tumors (SCLC) has identified genetic subtypes and provided insights into the mechanisms of this aggressive and deadly cancer.

1 5 6 7 8 9 26